Key terms
About CORT
Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company. It engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Menlo Park, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest CORT news
Yesterday
8:24am ET
Corcept Therapeutics management to meet with Truist
Yesterday
7:45am ET
Truist Financial Gives a Buy Rating to Corcept Therapeutics (CORT)
Feb 17
1:00am ET
Bad News for Corcept Therapeutics Stock: This New Risk Has Been Added
Feb 16
7:45am ET
Corcept Therapeutics price target raised to $42 from $36 at Truist
Feb 16
7:10am ET
Analysts Are Bullish on Top Healthcare Stocks: Corcept Therapeutics (CORT), Bio-Rad Laboratories (BIO)
Feb 16
6:20am ET
Analysts’ Top Healthcare Picks: AngioDynamics (ANGO), Corcept Therapeutics (CORT)
Feb 16
6:14am ET
Corcept Therapeutics price target raised to $38 from $28 at H.C. Wainwright
Feb 15
4:52pm ET
Corcept Therapeutics announces preliminary results from CATALYST study
Feb 15
4:45pm ET
Corcept Therapeutics reports Q4 EPS 28c, consensus 26c
Feb 15
4:23pm ET
Corcept Therapeutics Reports Latest Quarterly Results and Update
Jan 24
1:29am ET
Corcept Therapeutics: Hold Rating Amidst Generic Competition and Legal Challenges
Jan 23
7:40am ET
Wall Street Analysts Are Bullish on Top Healthcare Picks
Jan 23
6:25am ET
Corcept Therapeutics price target lowered to $23 from $27 at Leerink
Jan 11
1:41am ET
Leerink Partners Keeps Their Hold Rating on Corcept Therapeutics (CORT)
Jan 11
1:31am ET
Analysts Offer Insights on Healthcare Companies: Corcept Therapeutics (CORT), Incyte (INCY) and Nkarta (NKTX)
Jan 09
7:50am ET
Analysts Offer Insights on Healthcare Companies: Paragon 28 (FNA), Intellia Therapeutics (NTLA) and Corcept Therapeutics (CORT)
Jan 08
8:23am ET
Corcept Therapeutics announces $200M stock buyback
Jan 08
8:23am ET
Corcept Therapeutics guides FY24 revenue at $600M-$630M, consensus $513.9M
Jan 08
8:22am ET
Corcept Therapeutics sees Q4 revenue at $135.4M, consnesus $127.9M
Jan 05
11:01am ET
Biotech Alert: Searches spiking for these stocks today
Jan 04
11:57pm ET
Leerink Partners Keeps Their Hold Rating on Corcept Therapeutics (CORT)
Jan 04
11:13am ET
Biotech Alert: Searches spiking for these stocks today
Jan 02
12:25pm ET
Balancing Near-term Risks with Long-term Potential: A Buy Rating for Corcept Therapeutics
Jan 02
12:18pm ET
Corcept Therapeutics price target lowered to $28 from $34 at H.C. Wainwright
Jan 02
9:43am ET
Piper still constructive on Corcept despite patent case ‘disappointing’ outcome
Jan 02
8:05am ET
Corcept Therapeutics says court finds patents not infringed
Jan 02
7:35am ET
Corcept selloff today ‘ideal buying opportunity,’ says Canaccord
Jan 02
7:31am ET
Corcept sinks after judge rules for Teva in Korlym patent case
Jan 02
2:16am ET
Corcept (NASDAQ:CORT) Faces Setback in Patent Case; Shares Decline
No recent news articles are available for CORT
No recent press releases are available for CORT
CORT Financials
Key terms
Ad Feedback
CORT Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
CORT Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range